Epanova + Lovaza

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Hypertriglyceridemia

Conditions

Severe Hypertriglyceridemia

Trial Timeline

Oct 1, 2014 โ†’ Jul 1, 2015

About Epanova + Lovaza

Epanova + Lovaza is a phase 1 stage product being developed by AstraZeneca for Severe Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02189252. Target conditions include Severe Hypertriglyceridemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02189252Phase 1Completed

Competing Products

20 competing products in Severe Hypertriglyceridemia

See all competitors